Search Results | Blood | American Society of Hematology

1-20 of 93

2 3 4 5

Sort by

Sort Order Select

Journal Articles

T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?

Philippe Moreau, Cyrille Touzeau

Blood (2022) 139 (26): 3681–3687.

DOI: https://doi.org/10.1182/blood.2021014611

Published: 2022

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

DOI: https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Blood (2022) 139 (4): 492–501.

DOI: https://doi.org/10.1182/blood.2020010439

Published: 2022

Includes: Supplemental data

Journal Articles

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Blood (2021) 138 (25): 2686–2695.

DOI: https://doi.org/10.1182/blood.2021011285

Published: 2021

Includes: Supplemental data

Journal Articles

A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft

Patrice Chevallier, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Yannick Le Bris, Marion Eveillard, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Anne Lok, Cyrille Touzeau, Thomas Gastinne, Benoit Tessoulin, Maxime Jullien, Sophie Vantyghem, Philippe Moreau, Steven Le Gouill, Marie C Bene, Thierry Guillaume

Blood (2021) 138 (Supplement 1): 1812.

DOI: https://doi.org/10.1182/blood-2021-149534

Published: 2021

Journal Articles

Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy

Blood (2021) 138 (Supplement 1): 3465.

DOI: https://doi.org/10.1182/blood-2021-149405

Published: 2021

Journal Articles

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)

Aurore Perrot, Valérie Lauwers-Cances, Cyrille Touzeau, Olivier Decaux, Cyrille Hulin, Magaret Macro, Anne-Marie Stoppa, Marie Lorraine Chretien, Lionel Karlin, Clara Mariette, Caroline Jacquet, Murielle Roussel, Coralie Guillemot, Laure Devlamynck, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal

Blood (2021) 138 (Supplement 1): 464.

DOI: https://doi.org/10.1182/blood-2021-146040

Published: 2021

Journal Articles

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine

Blood (2021) 138 (Supplement 1): 2895.

DOI: https://doi.org/10.1182/blood-2021-149139

Published: 2021

Journal Articles

Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy

Blood (2021) 138 (Supplement 1): 254.

DOI: https://doi.org/10.1182/blood-2021-149476

Published: 2021

Journal Articles

Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study

Alice Garnier, Maxime Jullien, Thierry Guillaume, Pierre Peterlin, Amandine Le Bourgeois, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Cyrille Touzeau, Thomas Gastinne, Anne Lok, Benoit Tessoulin, Sophie Vantyghem, Marie C Bene, Philippe Moreau, Steven Le Gouill, Patrice Chevallier

Blood (2021) 138 (Supplement 1): 4914.

DOI: https://doi.org/10.1182/blood-2021-146826

Published: 2021

Journal Articles

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients

Blood (2021) 138 (Supplement 1): 3908.

DOI: https://doi.org/10.1182/blood-2021-149178

Published: 2021

Journal Articles

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3911.

DOI: https://doi.org/10.1182/blood-2021-150439

Published: 2021

Journal Articles

Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)

Magaret Macro, Cyrille Touzeau, Clara Mariette, Salomon Manier, Sabine Brechignac, Laure Vincent, Benjamin Hebraud, Olivier Decaux, Samantha Schulmann, Caroline Bureau Lenoir, Pascal Godmer, Jean-Jacques Parienti, Xavier Leleu

Blood (2021) 138 (Supplement 1): 83.

DOI: https://doi.org/10.1182/blood-2021-148152

Published: 2021

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

DOI: https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

Sensitivity to venetoclax: the B-side of myeloma?

Cyrille Touzeau, Philippe Moreau

Blood (2021) 137 (26): 3582–3583.

DOI: https://doi.org/10.1182/blood.2021011146

Published: 2021

Journal Articles

Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Blood (2020) 136 (Supplement 1): 28–30.

DOI: https://doi.org/10.1182/blood-2020-134935

Published: 2020

Journal Articles

Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study

Thomas Chalopin, Nicolas Vallet, MD, Marlene Ochmann, MD, Mourad Tiab, Pascal Godmer, Carole Barin, Olivier Theisen, MD, Olivier Herault, MD PhD, Emmanuel Gyan, MD PhD, Lotfi Benboubker, MD, Philippe Moreau, MD, Herve Avet-Loiseau, Cyrille Touzeau

Blood (2020) 136 (Supplement 1): 15–17.

DOI: https://doi.org/10.1182/blood-2020-139436

Published: 2020

Journal Articles

HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations

Blood (2020) 136 (Supplement 1): 20–22.

DOI: https://doi.org/10.1182/blood-2020-136000

Published: 2020

Journal Articles

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Blood (2020) 136 (Supplement 1): 39.

DOI: https://doi.org/10.1182/blood-2020-134538

Published: 2020

Journal Articles

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Blood (2020) 136 (Supplement 1): 18–20.

DOI: https://doi.org/10.1182/blood-2020-134928

Published: 2020

2 3 4 5

NARROW

T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft

Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine

Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy

Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Sensitivity to venetoclax: the B-side of myeloma?

Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study

HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only